Pharmacokinetics of sedatives – Understanding a modifiable risk factor for pediatric delirium

NIH RePORTER · NIH · R01 · $656,172 · view on reporter.nih.gov ↗

Abstract

Project Summary/Abstract Over the past decade, delirium – identified as an unexplained alteration in cognitive function as a result of another clinical condition – has become recognized as a public health emergency for adults with critical illnesses. In this patient population, delirium is associated with mortality, morbidity, increased length of hospital stays and increased health care costs. We have developed a delirium screening tool to assess delirium in children of all ages. This score, the Cornell Assessment of Pediatric Delirium, has been validated with several psychiatrists at Cornell University and is starting to be used as a part of clinical care. While the development of delirium is multifactorial, sedatives represent a modifiable risk factor for clinicians to consider. To date, there is no pharmacokinetic information to guide clinicians on which sedatives are linked to delirium development. Based on extensive preliminary evidence, we suspect that benzodiazepine-based sedation is related to delirium development and may be affected by drug clearance and serum concentrations. We will also determine if other commonly used narcotics and other agents are associated with delirium development independent of benzodiazepine effects. We will test these two specific aims in a multi-centered (n = 3) study with analysis done at the University of Pittsburgh and University of Buffalo.

Key facts

NIH application ID
10222740
Project number
5R01HD099284-03
Recipient
CHILDREN'S RESEARCH INSTITUTE
Principal Investigator
MICHAEL JAMES BELL
Activity code
R01
Funding institute
NIH
Fiscal year
2021
Award amount
$656,172
Award type
5
Project period
2019-09-01 → 2024-07-31